{"id":"fb825","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":{"chemblId":"CHEMBL4297952","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, FB825 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"FB825 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:53:33.548Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05008965","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma","status":"RECRUITING","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2021-07-27","conditions":"Allergic Asthma","enrollment":100},{"nctId":"NCT06397911","phase":"PHASE2","title":"Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2024-08-08","conditions":"Atopic Dermatitis","enrollment":90},{"nctId":"NCT05952986","phase":"PHASE1","title":"A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults","status":"UNKNOWN","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2023-05-03","conditions":"Atopic Dermatitis","enrollment":22},{"nctId":"NCT04413942","phase":"PHASE2","title":"Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis","status":"UNKNOWN","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2020-03-10","conditions":"Atopic Dermatitis","enrollment":99},{"nctId":"NCT05059509","phase":"PHASE2","title":"Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2020-02-06","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT03758716","phase":"PHASE2","title":"An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Fountain Biopharma Inc.","startDate":"2017-07-03","conditions":"Atopic Dermatitis","enrollment":12},{"nctId":"NCT02309762","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers","status":"COMPLETED","sponsor":"Fountain Biopharma Inc.","startDate":"2015-03","conditions":"Healthy","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"FB825","genericName":"FB825","companyName":"Oneness Biotech Co., Ltd.","companyId":"oneness-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FB825 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}